Dapirolizumab pegol (DZP) Phase 3 study presentations in SLE to show efficacy results across multiple clinical endpoints, including low disease activity/remission, flares, fatigue, joint pain and ...
The FDA approved Scancell's phase 3 trial of iSCIB1+ for advanced melanoma, focusing on progression-free survival as a ...
Poster #1654 highlights clinically meaningful and durable increases in circulating neutrophils observed with mavorixafor treatment +/- G-CSF over 6-month study Poster #1669 highlights findings that ...
Add Yahoo as a preferred source to see more of our stories on Google. Merck KGaA's antibody-drug conjugate (ADC) Merck KGaA's antibody-drug conjugate (ADC), precemtabart tocentecan (Precem-TcT), has ...
Hosted on MSN
MindMed outlines 2026 Phase III trial readouts and advances MM120 commercialization with new CFO
Earnings Call Insights: Mind Medicine (MindMed) Inc. (MNMD) Q2 2025 CEO Robert Barrow highlighted that MindMed remains "on track with enrollment with our three pivotal Phase III trials for our lead ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Use of alternative endpoints in phase 3 oncology trials ...
Bristol Myers Squibb (NYSE:BMY) in collaboration with Johnson & Johnson today announced the decision to stop the Phase 3 Librexia ACS trial evaluating the efficacy and safety of milvexian when added ...
The FDA cleared the investigational new drug (IND) application for a global phase 3 registrational trial of iSCIB1+, a DNA ...
The U.S. Food and Drug Administration (FDA) has cleared an investigational new drug application for a registrational phase 3 clinical trial of iSCIB1+ for patients with advanced melanoma, a step that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results